Sarepta Therapeutics (SRPT) U.K.-Specific Hold Concerns 'Overblown' - William Blair

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. BILL
4. ADI
5. MRK
6. MRNA
7. LOW
8. COTY
9. RARE
10. TJX

Go back to Sarepta Therapeutics (SRPT) U.K.-Specific Hold Concerns 'Overblown' - William Blair

JPMorgan on Sarepta Therapeutics (SRPT): Any Material Downside is Overdone

February 9, 2018 11:45 AM EST

JPMorgan maintains Overweight on Sarepta Therapeutics (NASDAQ: SRPT).

Analyst Anupam Rama defends the stock after speaking with management and states that any material downside is overdone.

For an analyst ratings summary and ratings history on Sarepta Therapeutics... More

Pre-Open Movers 02/09: (PIRS) (FEYE) (NVDA) Higher; (TNDM) (EXPE) (WWD) Lower (more...)

February 9, 2018 9:30 AM EST

Pre-Open Movers

Alliance One Int'l (NYSE: AOI) 30.8% HIGHER; Total sales and other operating revenues increased 5.1% to $477.8 million primarily due to the larger South American crop and a 4.9% increase in average sales prices due to product mi

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) 28.4% LOWER; announced the pricing of an underwritten public offering of 30 million shares of its common stock at a price to the public of $2.00 per share.

MobileIron (NASDAQ: MOBL)... More

Sarepta Therapeutics' (SRPT) Golodirsen Study Halted in UK- EPVantage

February 9, 2018 7:45 AM EST

(Updated - February 9, 2018 7:52 AM EST)

Weakness in Sarepta Therapeutics (NASDAQ: SRPT) Friday morning was tied to a report that its UK study of golodirsen was halted.

A report from... More